Loading publications…
The last 5 uploaded publications
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
Elaine Sanij, Katherine M. Hannan, Jiachen Xuan, Shunfei Yan, Jessica E. Ahern, Anna Trigos, Natalie Brajanovski, Jinbae Son, Keefe T. Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J. Wakefield, Daniel Frank, Sarah Ellis, Carleen Cullinane, Jian Kang, Gretchen Poortinga, Purba Nag, Andrew J. Deans, Kum Kum Khanna, Linda Mileshkin, Grant A. McArthur, John Soong, Els M.J.J. Berns, Ross D. Hannan, Clare L. Scott, Karen E. Sheppard, Richard B. Pearson (2020). CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer. , 11(1), DOI: https://doi.org/10.1038/s41467-020-16393-4.
Article63 days agoAbstract PR13: Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade serous ovarian cancer
Elaine Sanij, Katherine M. Hannan, Jiachen Xuan, Shunfei Yan, Jessica Ahern, Anna Trigos, Natalie Brajanovski, Jinbae Son, Keefe T. Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J. Wakefield, Sarah Ellis, Carleen Cullinane, Gretchen Poortinga, Kum Kum Khanna, Linda Mileshkin, Grant A. McArthur, John Soong, Els M.J.J. Berns, Ross D. Hannan, Clare L. Scott, Karen E. Sheppard, Richard B. Pearson (2020). Abstract PR13: Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade serous ovarian cancer. , 26(13_Supplement), DOI: https://doi.org/10.1158/1557-3265.ovca19-pr13.
Article63 days agoInhibition of RNA Polymerase I Transcription Activates Targeted DNA Damage Response and Enhances the Efficacy of PARP Inhibitors in High-Grade Serous Ovarian Cancer
Elaine Sanij, Katherine M. Hannan, Shunfei Yan, Jiachen Xuan, Jessica E. Ahern, Keefe T. Chan, Jinbae Son, Olga Kondrashova, Elizabeth Lieschke, Matthew J. Wakefield, Anna Trigos, Daniel Frank, Sarah Ellis, Carleen Cullinane, Jian Kang, Gretchen Poortinga, Purba Nag, Kum Kum Khanna, Linda Mileshkin, Grant A. McArthur, John Soong, Els M.J.J. Berns, Ross D. Hannan, Clare L. Scott, Karen E. Sheppard, Richard B. Pearson (2019). Inhibition of RNA Polymerase I Transcription Activates Targeted DNA Damage Response and Enhances the Efficacy of PARP Inhibitors in High-Grade Serous Ovarian Cancer. , DOI: https://doi.org/10.1101/621623.
Preprint63 days agoMethylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
Olga Kondrashova, Monique Topp, Ksenija Nesic, Elizabeth Lieschke, Gwo‐Yaw Ho, Maria I. Harrell, Giada V. Zapparoli, Alison Hadley, Robert Holian, Emma Boehm, Valerie Heong, Elaine Sanij, Richard B. Pearson, John J. Krais, Neil Johnson, Orla McNally, Sumitra Ananda, Kathryn Alsop, Karla J. Hutt, Scott H. Kaufmann, Kevin Lin, Thomas C. Harding, Nadia Traficante, Georgia Chenevix‐Trench, A. Green, Penelope M. Webb, Dorota M. Gertig, Sián Fereday, Suzanne Moore, Jillian A. Hung, K.R. Harrap, T. Sadkowsky, Nirmala Pandeya, M. Malt, A. Mellon, R. Paul Robertson, T. Vanden Bergh, Milissa U. Jones, P. Mackenzie, J. Maidens, K. Nattress, Yoke-Eng Chiew, Annie Stenlake, Harold C. Sullivan, Brian M. Alexander, P. Ashover, Stephen M. Brown, T. Corrish, L. Green, L. M. Jackman, Kaltin Ferguson, Karla Martin, A. Martyn, B. Ranieri, J. White, V. Jayde, Pam Mamers, Leanne Bowes, Laura Galletta, Daniel A. Giles, Joy Hendley, Thomas Schmidt, H. Shirley, C. Ball, Christian D. Young, S. Viduka, Hang Tran, Sanela Bilic, Lydia Glavinas, Julia Brooks, R. Stuart‐Harris, Fred Kirsten, J Rutovitz, P. Clingan, Akisha Glasgow, Anthony Proietto, Stephen Braye, Geoffrey Otton, Jenny Shannon, Tony Bonaventura, James Stewart, Stephen Begbie, Michael Friedlander, Debra Bell, Sally Baron‐Hay, A. Ferrier, G. Gard, David Nevell, Nick Pavlakis, Susan Valmadre, B. Young, C. Camaris, R. Crouch, L. Edwards, Neville F. Hacker, Donald E. Marsden, G.M. Robertson, Philip Beale, Jane Beith, Jonathan Carter (2018). Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. , 9(1), DOI: https://doi.org/10.1038/s41467-018-05564-z.
Article63 days ago